Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $23.20

Stoke Therapeutics, Inc. (NASDAQ:STOK) has received an average recommendation of “Buy” from the seven analysts that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $23.20.

Several equities analysts recently weighed in on STOK shares. HC Wainwright reduced their target price on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday. Chardan Capital restated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, Cantor Fitzgerald raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Wednesday, May 14th.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK opened at $11.55 on Monday. The firm has a market cap of $630.63 million, a P/E ratio of 14.62 and a beta of 1.14. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $16.15. The firm’s 50 day moving average price is $10.36 and its 200 day moving average price is $9.58.

Insider Activity

In related news, insider Barry Ticho sold 6,471 shares of the firm’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total value of $64,904.13. Following the transaction, the insider owned 25,782 shares in the company, valued at approximately $258,593.46. This trade represents a 20.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently made changes to their positions in STOK. GAMMA Investing LLC lifted its holdings in shares of Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock valued at $36,000 after acquiring an additional 5,084 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Stoke Therapeutics in the fourth quarter valued at about $63,000. Teacher Retirement System of Texas acquired a new position in shares of Stoke Therapeutics during the fourth quarter worth about $113,000. AlphaQuest LLC purchased a new stake in shares of Stoke Therapeutics in the first quarter worth about $72,000. Finally, US Bancorp DE grew its stake in shares of Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after buying an additional 11,108 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.